Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …

Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
affected more than 529 million people, and today the world is facing different mutant strains …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and
limited vaccine availability for the general population in most countries, the monoclonal …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …